Contact

Angiotensin Type 2 (AT2) Receptor Agonists And Uses Thereof

Louwe De Vries et al., United States Patent De Vries et al (2019) - PMID: 19861351

Product(s) used in this publication:  Specialty Peptides

Abstract

 

 

Considerable progress in our understanding of the role of the angiotensin II type 2 (AT(2)) receptor in the development of cardiac hypertrophy and coronary artery disease has been achieved using in vitro and in vivo animal models. Our understanding in humans, however, has been hindered by the lack of availability of specific AT(2) receptor agonists and antagonists suitable for human study. Nevertheless, an alternative approach involving genotyping humans for a functional polymorphism within the AT(2) receptor gene (-1332G/A) has been used in several association studies to elucidate the pathogenic role of the AT(2) receptor in cardiovascular disease. Both the A allele and the G allele have independently been associated with left ventricular remodelling. However, the methods of measuring left ventricular mass, sodium balance, age and degree of remodelling appear to influence the outcome. An association of carriers of the G allele and premature coronary artery disease has also been established, particularly in males presenting with stenotic atherosclerosis requiring revascularisation. At the molecular level, it remains unclear as to whether carriers of the G allele express more or fewer AT(2) receptors when compared to carriers of the A allele. Consequently, it is presently not possible to definitively interpret the role of the AT(2) receptor in human cardiovascular disease from these association studies.

Stay in touch and be the first to receive the latest news!